Transposition of Internal Limiting Membrane in the Treatment of Macular Holes. A Descriptive Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Presence of the internal limiting membrane transposed into foveal region
研究概览
简要总结
Macular hole is an infrequent retinal pathology (2 to 4/1000) which most often affects people aged over 60, and twice common in women than men.
The vast majority of cases are idiopathic. Without treatment, the macular hole evolves through a series of stages until the extension of the diameter (up to 500 microns and higher values). With a fully developed macular hole, patients complain of metamorphopsia and decreased visual acuity.
This pathology has clearly benefited from advances in microsurgery and better understanding of its pathophysiology. Macular hole treatment has evolved to include small-gauge pars plana vitrectomy with or without internal limiting membrane (ILM) peeling and placement of intraocular gas tamponade.
The postoperative closure rate is close to 80%, but strongly depends on the initial characteristics of the hole, its diameter remaining the main prognostic factor. Thus for macular holes <400 microns, the closure rate is close to 92% dropping to 56% for macular holes above 400 microns. In case of surgical failure, one or more reoperations can be proposed, but with a lower closure rate.
The quest for a surgical technique presenting a greater success rate is a common goal to all retinologists.
Here the investigators propose a new surgical technique, derived from the FLAP method, and consisting of an inner limiting membrane transposition.
The objective of this study is to evaluate the feasibility of a new surgical technique for the treatment of macular holes already operated but without macular hole closure, allowing these patients a new therapeutic alternative. The success of this technique will be confirmed by detecting postoperatively the presence of the transposed internal limiting membrane into the foveal region.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient aged over 18,
- •Patient who already received at least a macular hole surgery,
- •Period of at least 4 months since last macular hole surgery,
- •Patient who underwent peeling of the internal limiting membrane,
- •Presents in OCT an open criteria macular hole,
- •The presence of a cataract in the preoperative clinical examination is not against indication. Its removal can be integrated to the surgery,
- •Patient who signed the consent form
排除标准
- •Patient with against-indication or surgical anesthetic,
- •Macular Hole "flat open" or closed,
- •No progressive macular pathology other than the presence of a macular hole (retinal detachment, Macular degeneration related to age) Idiopathic and secondary macular holes are eligible if they have already been operated with the prior internal limiting membrane coat.
- •Patient unaffiliated or not the beneficiary of a social security system, or equivalent health insurance,
- •Pregnant or breastfeeding women,
- •Absence of patient consent,
- •Patient in exclusion period involved in another study,
- •Patient on administrative or judicial supervision
结局指标
主要结局
Presence of the internal limiting membrane transposed into foveal region
时间窗: 8 weeks after surgery
次要结局
- The patient's visual comfort will be assessed using the NEI-VFQ-25 Quality of Life questionary(8 weeks after surgery)
- Visual acuity will be assessed by clinical examination(8 weeks after surgery)
- The size and appearance of the macular hole will be assessed by optical coherence tomography (OCT)(8 weeks after surgery)